PROTON PUMP INHIBITORS: PROLONGED INTAKE  AND ADVERSE EFFECTS.

Anna Dominiczak; Agata Janczak; Martyna Wołek; Katarzyna Mazurek; Maciej Bara

doi:10.56782/pps.226

Data publikacji : 2024-11-06

Tom 22 Nr 4 (2024)

PROTON PUMP INHIBITORS: PROLONGED INTAKE AND ADVERSE EFFECTS.

Anna Dominiczak

Agata Janczak

Martyna Wołek

Katarzyna Mazurek

Maciej Bara

DOI: https://doi.org/10.56782/pps.226

Abstrakt

Proton pump inhibitors (PPI) are commonly used medicines in management of the upper gastrointestinal (GI) tract diseases. The perception of PPIs as relatively safe contributes to their frequent overprescription and misuse. One of the main reasons for PPIs overprescription is unjustified prophylaxis of bleeding in the course of non-steroid anti inflammatory drugs therapy. Prolonged PPI intake is associated with several side effects due to intestinal dysbiosis, including increased risk of GI and respiratory infections, as well as small intestine bacterial overgrowth (SIBO). Other reported adverse effects include malabsorption of vitamins and micro- and macroelements, hypergastrinemia, neurological, cardiovascular and renal complications and stomach cancer. The aim of this paper was to assess the scale of misuse and overuse of PPI and to look closely on the potential side effects of treatment with PPIs. However, during the review of the available literature, many of the analyzed studies yielded conflicting results, indicating the need for further in-depth research to draw reliable conclusions.

Podobne artykuły

Agnieszka Kalicka, Natalia Tarłowska, COUNTERFEIT AND ILLEGAL MEDICINAL PRODUCTS AS AN EXAMPLE OF DRUGS THAT DO NOT MEET THE BASIC QUAITY REQUIREMENTS , Prospects in Pharmaceutical Sciences: Tom 21 Nr 4 (2023)
Barbara Krzemińska, Gabriela Szewczyk, Cotoneaster horizontalis Decne. (Rosaceae) - the medicinal or just ornamental species? , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Paulina Dąbrowska, Michał Żuber, Michał Dacka, Efficacy and Safety of Bempedoic Acid in Lipid Disorder Therapy: A Review of Clinical Trials , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)
Kacper Jasiński, Paulina Oleksa, Daria Żuraw, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Bartosz Pawłowski, THE EFFECTIVENESS OF THE IMMUNE-BOOSTING PREPARATIONS IN PREVENTION AND TREATMENT OF RESPIRATORY INFECTIONS , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)
Bartłomiej Kałaska, Joanna Mikłosz, Emilia Sokołowska, Andrzej Mogielnicki, BLASKI I CIENIE WSPÓŁCZESNEJ FARMAKOTERAPII ANTYKOAGULACYJNEJ , Prospects in Pharmaceutical Sciences: Tom 14 Nr 10 (2016)
Ms., Monika Czerwińska, PLANT MATERIALS USED IN EYE DISEASES - FROM USE IN TRADITIONAL MEDICINE TO RESEARCH IN ANTIOXIDANT, ANTI-INFLAMMATORY AND ANTIBACTERIAL ACTIVITY , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)
Nazan Comlekcioglu, Ashabil Aygan, Mustafa Sevindik, Uğur Comlekcioglu, Comparative analysis of phytochemical properties of extracts obtained from flowers and leaves of Astragalus angustifolius collected from different locations , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)
Paulina Oleksa, Daria Żuraw, Kacper Jasiński, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Karolina Haczkur-Pawłowska, Drugs and chemical substances inducing diabetes - review of the literature , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Tomasz Pieńko, KAPSAICYNA - WŁAŚCIWOŚCI, ZASTOSOWANIA I PERSPEKTYWY , Prospects in Pharmaceutical Sciences: Tom 11 Nr 2 (2013)
Angelika Lis, Katarzyna Wyszomierska, Katarzyna Znajdek, Łukasz Szeleszczuk, Monika Zielińska-Pisklak, ZJAWISKO FOTONADWRAŻLIWOŚCI – ISTOTNE DZIAŁANIE NIEPOŻĄDANE POWSZECHNIE STOSOWANYCH LEKÓW , Prospects in Pharmaceutical Sciences: Tom 19 Nr 3 (2021)

<< < 1 2 3 4 5 6 > >>

Możesz również Rozpocznij zaawansowane wyszukiwanie podobieństw dla tego artykułu.

Szczegóły

Bibliografia

Statystyki

Autorzy

Pobierz pliki

PDF

Zasady cytowania

Dominiczak, A., Agata Janczak, Martyna Wołek, Katarzyna Mazurek, & Maciej Bara. (2024). PROTON PUMP INHIBITORS: PROLONGED INTAKE AND ADVERSE EFFECTS. Prospects in Pharmaceutical Sciences, 22(4), 51–58. https://doi.org/10.56782/pps.226

Wskaźniki altmetryczne

Cited by / Share

Licencja

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa 4.0 Międzynarodowe.

Bibliografia

1. Ward, R.M.; Kearns, G.L. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr. Drugs. 2013, 15(2), 119-131. doi: 10.1007/s40272-013-0012-x

2. Wedemeyer, R.S.; Blume, H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014, 37(4), 201-11. doi: 10.1007/s40264-014-0144-0

3. Stedman, C.A.; Barclay, M.L. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment. Pharmacol. Ther. 2000, 14(8), 963-78. doi: 10.1046/j.1365-2036.2000.00788.x

4. Crafa, P.; Franceschi, M.; Rodriguez-Castro, K.I.; Franzoni, L.; Russo, M.; Brandimarte, G.; Tursi, A.; Rugge, M.; Di Mario, F. PPIs and gastric cancer: any causal relationship? Acta Biomed. 2023, 94(3), Art. No: e2023096. doi: 10.23750/abm.v94i3.14105

5. Kazberuk, M.; Brzósko, S.; Hryszko, T.; Naumnik, B. Nadużywanie inhibitorów pompy protonowej i jego konsekwencje. Postepy Hig. Med Dosw. 2016, 70(null), 1112-1116. doi: 10.5604/17322693.1222106

6. Chudek, J. Stosowanie inhibitorów pompy protonowej w profilaktyce choroby wrzodowej u chorych leczonych niesteroidowymi lekami przeciwzapalnymi. Gastroenterologia Kliniczna 2012, 4(1), 33-39.

7. Ahmed, A.; Clarke, J.O.; Proton Pump Inhibitors (PPI). [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557385/

8. Shanika, L.G.T.; Reynolds, A.; Pattison, S.; Braund, R. Proton pump inhibitor use: systematic review of global trends and practices. Eur. J. Clin. Pharmacol. 2023, 79(9), 1159-1172. doi: 10.1007/s00228-023-03534-z

9. ClinCalc.com. Available online: https://clincalc.com/About.aspx (accessed on 30 June 2024).

10. El Rouby, N.; Lima, J.J.; Johnson, J.A. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin. Drug Metab. Toxicol. 2018, 14(4), 447-460. doi: 10.1080/17425255.2018.1461835

11. Gendre, P.; Mocquard, J.; Huon, J.F. Appropriateness of proton pump inhibitors prescription in patient admitted to hospital: An observational study. Ann. Pharm. Fr. 2023, 81(4), 596-603. doi: 10.1016/j.pharma.2022.11.003

12. Ahrens, D.; Behrens, G.; Himmel, W.; Kochen, MM.; Chenot, J.F. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int. J. Clin. Pract. 2012, 66(8), 767-773. doi: 10.1111/j.1742-1241.2012.02973.x

13. Gendre, P.; Mocquard, J.; Artarit, P.; Chaslerie, A.; Caillet, P.; Huon, J.F. (De)Prescribing of proton pump inhibitors: what has changed in recent years? an observational regional study from the French health insurance database. BMC Prim. Care. 2022, 23(1), Art. No: 341. doi: 10.1186/s12875-022-01941-2

14. Buda, V.; Prelipcean, A.; Cristescu, C.; Roja, A.; Dalleur, O.; Andor, M.; Danciu, C.; Ledeti, A.; Dehelean, C.A.; Cretu, O. Prescription Habits Related to Chronic Pathologies of Elderly People in Primary Care in the Western Part of Romania: Current Practices, International Recommendations, and Future Perspectives Regarding the Overuse and Misuse of Medicines. Int. J. Environ. Res. Public Health. 2021, 18(13), Art. No: 7043. doi: 10.3390/ijerph18137043

15. Blume, H.; Donath, F.; Warnke, A.; Schug, B.S. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006, 29(9), 769-84. doi: 10.2165/00002018-200629090-00002

16. Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne. Dz.U. 2001 nr 126 poz. 1381. Available online: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20011261381 (accessed on 07 October 2024)

17. Zhang, J.; Zhang, C.; Zhang, Q.; Yu, L.; Chen, W.; Xue, Y.; Zhai, Q. Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota. BMC Microbiol. 2023, 23(1), 171. doi: 10.1186/s12866-023-02895-w

18. Kwok, C.S.; Arthur, A.K.; Anibueze, C.I.; Singh, S.; Cavallazzi, R.; Loke, Y.K.; Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 2012, 107(7), 1011-9. doi: 10.1038/ajg.2012.108

19. McDonald, E.G.; Milligan, J.; Frenette, C.; Lee, T.C. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Intern. Med. 2015, 175(5), 784–791. doi:10.1001/jamainternmed.2015.42

20. Haastrup, P.F.; Thompson, W.; Søndergaard, J.; Jarbøl, D.E. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin. Pharmacol. Toxicol. 2018, 123(2), 114-121. doi: 10.1111/bcpt.13023

21. Nelis, G.F.; Engelage, A.H.; Samson, G. Does long-term inhibition of gastric acid secretion with omeprazole lead to small intestinal bacterial overgrowth? Neth. J. Med. 1994, 45, 93–100.

22. Pereira, S.P.; Gainsborough, N.; Dowling, R.H. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment. Pharmacol. Ther. 1998, 12, 99–104. doi: 10.1046/j.1365-2036.1998.00275.x

23. Su, T.; Lai, S.; Lee, A.; He, X.; Chen, S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J. Gastroenterol. 2018, 53(1), 27-36. doi: 10.1007/s00535-017-1371-9

24. Weitsman, S.; Celly, S.; Leite, G.; Mathur, R.; Sedighi, R.; Barlow, G.M. Effects of proton pump inhibitors on the small bowel and stool microbiomes. Dig. Dis. Sci. 2022, 67, 224–232. doi: 10.1007/s10620-021-06857-y.

25. Othman, F.; Crooks, C.J.; Card, T.R. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ 2016, 355, i5813. doi: 10.1136/bmj.i5813

26. de Jager, C.P.; Wever, P.C.; Gemen, E.F.; van Oijen, M.G.; van Gageldonk-Lafeber, A.B.; Siersema, P.D.; Kusters, G.C.; Laheij, R.J. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment. Pharmacol. Ther. 2012, 36(10), 941-949. doi: 10.1111/apt.12069

27. Lambert, A.A.; Lam, J.O.; Paik, J.J.; Ugarte-Gil, C.; Drummond, M.B.; Crowell, T.A. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015, 10(6), Art. No: e0128004. doi: 10.1371/journal.pone.0128004

28. Waldum, H.L.; Qvigstad, G.; Fossmark, R.; Kleveland, P.M.; Sandvik, A.K. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand. J. Gastroenterol. 2010, 45(4), 389-394. doi: 10.3109/00365520903477348

29. Reimer, C.; Søndergaard, B.; Hilsted, L.; Bytzer, P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009, 137(1), 80-87.e1. doi: 10.1053/j.gastro.2009.03.058

30. Lødrup, A.B.; Reimer, C.; Bytzer, P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand. J. Gastroenterol. 2013, 48(5), 515-522. doi: 10.3109/00365521.2012.746395

31. Fallahzadeh, M.K.; Borhani Haghighi, A.; Namazi, M.R. Proton pump inhibitors: predisposers to Alzheimer disease? J. Clin. Pharm. Ther. 2010, 35(2), 125-126. doi: 10.1111/j.1365-2710.2009.01100.x

32. Wu, B.; Hu, Q.; Tian, F.; Wu, F.; Li, Y.; Xu, T. A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci. Rep. 2021, 11(1), 10709. doi: 10.1038/s41598-021-90108-7

33. Dinesh, D.; Lee, J.S.; Scott, T.M.; Tucker, K.L.; Palacios N. Proton Pump Inhibitor Use and Cognitive Function in the Boston Puerto Rican Health Study. J. Gerontol. A. Biol. Sci. Med. Sci. 2023, 78(8), 1461-1470. doi: 10.1093/gerona/glac231

34. Ahn, N.; Wawro, N.; Baumeister, S.E.; Nolde, M.; Gerlach, R.; Tauscher, M.; Günter, A.; Güntner, F.; Rückert-Eheberg, I.M.; Meisinger, C.; Linseisen, J. Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany Drugs Aging. 2023, 40(7), 653-663. doi: 10.1007/s40266-023-01031-7

35. Castellana, C.; Pecere, S.; Furnari, M.; Telese, A.; Matteo, M.V.; Haidry, R.; Eusebi, L.H. Side effects of long-term use of proton pump inhibitors: practical considerations. Pol. Arch. Intern. Med. 2021, 131(6), 541-549. doi: 10.20452/pamw.15997

36. Langan, R.C.; Goodbred, A.J. Vitamin B12 Deficiency: Recognition and Management. Am. Fam. Physician 2017, 96(6), 384-389.

37. Swarnakari, K.M.; Bai, M.; Manoharan, M.P.; Raja, R.; Jamil, A.; Csendes, D.; Gutlapalli, S.D.; Prakash, K.; Desai, D.M.; Desai, A.; Khan, S. The Effects of Proton Pump Inhibitors in Acid Hypersecretion-Induced Vitamin B12 Deficiency: A Systematic Review (2022). Cureus. 2022, 14(11), Art. No: e31672. doi: 10.7759/cureus.31672

38. Losurdo, G.; Caccavo, N.L.B.; Indellicati, G.; Celiberto, F.; Ierardi, E.; Barone, M.; Di Leo, A. Effect of Long-Term Proton Pump Inhibitor Use on Blood Vitamins and Minerals: A Primary Care Setting Study. J. Clin. Med. 2023, 12(8), Art. No: 2910. doi: 10.3390/jcm12082910

39. Gommers, L.M.M.; Hoenderop, J.G.J.; de Baaij, J.H.F. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol. (Oxf). 2022, 235(4), Art. No: e13846. doi: 10.1111/apha.13846

40. Paudel, Y.; Najam, B.; Desai, H.N.; Illango, J.; Seffah, K.D.; Kumar, M.; Naveen, N.; Pachchipulusu, V.K.; Penumetcha, S.S. Use of Proton Pump Inhibitors and Risk of Fracture in Adults: A Review of Literature. Cureus 2023, 15(12), Art. No: e49872. doi: 10.7759/cureus.49872

41. Dado, D.N.; Loesch, E.B.; Jaganathan, S.P. A Case of Severe Iron Deficiency Anemia Associated with Long-Term Proton Pump Inhibitor Use. Curr. Ther. Res. Clin. Exp. 2017, 84, 1-3. doi: 10.1016/j.curtheres.2017.01.003

42. Imai, R.; Higuchi, T.; Morimoto, M.; Koyamada, R.; Okada, S. Iron Deficiency Anemia Due to the Long-term Use of a Proton Pump Inhibitor. Intern. Med. 2018, 57(6), 899-901. doi: 10.2169/internalmedicine.9554-17

43. Ariel, H.; Cooke, J.P. Cardiovascular Risk of Proton Pump Inhibitors. Methodist Debakey Cardiovasc. J. 2019, 15(3), 214-219. doi: 10.14797/mdcj-15-3-214.

44. Shiraev, T.P.; Bullen, A. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart Lung Circ. 2018, 27(4), 443-450. doi: 10.1016/j.hlc.2017.10.020

45. Song, H.J.; Seo, H.J.; Jiang, X.; Jeon, N.; Lee, Y.J.; Ha, I.H. Proton pump inhibitors associated with an increased risk of mortality in elderly: a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 2024, 80(3), 367-382. doi: 10.1007/s00228-023-03606-0

46. Parmar, M.P.; Kaleem, S.; Samuganathan, P.; Ishfaq, L.; Anne, T.; Patel, Y.; Bollu, S.; Vempati, R. Impact of Proton Pump Inhibitors on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review. Cureus 2023, 15(12), Art. No: e49883. doi: 10.7759/cureus.4988

47. Hart, E.; Dunn, T.E.; Feuerstein, S.; Jacobs, D.M. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019, 39, 443-453. doi: 10.1002/phar.2235

48. Malavade, P.; Hiremath, S. Proton Pump Inhibitors: More Indigestion than Relief? Indian J. Nephrol. 2017, 27(4), 249-257. doi: 10.4103/0971-4065.202824

49. Kamiński, T.; Michałowska, M.; Pawlak, D. Receptor węglowodorów aromatycznych (AhR) i jego endogenny agonista – siarczan indoksylu w przewlekłej chorobie nerek. Postepy Hig. Med. Dosw. 2017, 71, 624-632. doi: 10.5604/01.3001.0010.3843

50. Banoglu, E.; Jha, G.G.; King, R.S. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet. 2001, 26(4), 235-240. doi: 10.1007/BF03226377

51. Song, H.; Zhu, J.; Lu, D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst. Rev. 2014, 2014(12), Art. No: CD010623. doi: 10.1002/14651858.CD010623.pub2

52. Tran, T.H.; Myung, S.K.; Trinh, TTK. Proton pump inhibitors and risk of gastrointestinal cancer: A meta‑analysis of cohort studies. Oncol. Lett. 2023, 27(1), Art. No: 28. doi: 10.3892/ol.2023.14161

53. Kim, G.H. Proton Pump Inhibitor-Related Gastric Mucosal Changes. Gut Liver. 2021, 15(5), 646-652. doi: 10.5009/gnl20036

Anna Dominiczak

amdominiczak@gmail.com

Afiliacja:

a:1:{s:5:"en_US";s:28:"Medical University of Warsaw";} Poland